Effect of omega3 on fetuin level

Evaluation and Comparison of the Effectiveness of Herbal Omega3 Supplements (flax seed) and Animal Based Omega3 on Fetuin Level in Patient with Chronic Kidney Disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180820040839N1

Enrollment

Registered

2019-03-02

Start date

2018-12-16

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: chronic kidney disease. Condition 2: chronic kidney disease. Chronic kidney disease, stage 3 (moderate) Chronic kidney disease, stage 4 (severe)

Interventions

Intervention 1: Intervention group: The first group are 30 people who receive 2 tablet of 1 gram animal's omega3(fish oil) per day for 90 days from the Zakhravi factory in Tabriz . Intervention 2: In

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The patient above 18 years Gleumerolar Filtration Rate between15 to 60

Exclusion criteria

Exclusion criteria: Allergen to omega3 products Infection and inflamation disease

Design outcomes

Primary

Measure	Time frame
Mesurement of serum fetoin. Timepoint: Measurement of serum fetoin in the beginning of the study (before the intervention) and 90 days after medication. Method of measurement: fetoin kit in laboratory.	—

Secondary

Measure	Time frame
Measurement of seum HDL. Timepoint: Measurement of serum HDL levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: HDL kit in laboratory.;Measurement of seum LDL. Timepoint: Measurement of serum LDL levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: LDL kit in laboratory.;Measurement of seum TG. Timepoint: Measurement of serum TG levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: TG kit in laboratory.;Measurement of seum ESR. Timepoint: Measurement of serum ESR levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: ESR kit in laboratory.;Measurement of seum CRP. Timepoint: Measurement of serum CRP levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: CRP kit in laboratory.	—

Measure

Time frame

Measurement of seum HDL. Timepoint: Measurement of serum HDL levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: HDL kit in laboratory.;Measurement of seum LDL. Timepoint: Measurement of serum LDL levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: LDL kit in laboratory.;Measurement of seum TG. Timepoint: Measurement of serum TG levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: TG kit in laboratory.;Measurement of seum ESR. Timepoint: Measurement of serum ESR levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: ESR kit in laboratory.;Measurement of seum CRP. Timepoint: Measurement of serum CRP levels early in the study (before the start of the intervention) and 90 days after starting the medication. Method of measurement: CRP kit in laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Khodadustan

Shahre-kord University of Medical Sciences

e.khodadustan@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026